H. Matthys (Freiburg, Germany), M. Fletcher (Warwick, United Kingdom)
Inspiratory profiles and consistency of behaviour regarding dose delivery characteristics of two dry powder inhalers in COPD patients
C. J. Badiola, J. L. Izquierdo (Madrid, Guadalajara, Spain)
|  |
Alveolar absorption and systemic bioactivity of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease
D. K. C. Lee, B. J. Lipworth (Dundee, United Kingdom)
| |
Systemic inflammatory response during one year follow-up in patients with COPD
E. C. Creutzberg, D. S. Postma, W. C. J. Hop, N. A. Vermue, J. E. M. G. Derks, E. F. M. Wouters (Maastricht, Horn, Groningen, Rotterdam, Zeist, The Netherlands)
| |
Prevalence of gastroesophageal reflux (GER) in patients with chronic obstructive pulmonary disease (COPD)
M. Smedek, E. Sosonowska, Z. Adamowicz, A. Doboszynska, M. Karasinska, I. Tomaszewska (Warsaw, Poland)
| |
Management of chronic obstructive pulmonary disease: compliance with the Swiss guidelines
K. M. Fritsch, M. L. Jacot, A. Klarer, F. Wick, P. Bruggmann, R. Thurnheer (Munsterlingen, Switzerland)
| |
Accuracy of chest x-ray film interpretation by junior doctors in an acute chronic obstructive pulmonary disease (COPD) service
A. Sibanda, E. Johnson, A. L. Pilling, K. Wood, R. J. Wolstenholme (Wigan, United Kingdom)
| |
D-dimers in patients with chronic obstructive pulmonary disease with or without secondary secondary erythrocytosis
G. Ilonidis, G. Anogianakis, A. Anogeianaki, I. Giavazis, E. Theofilogiannakos, P. Glouftsios, P. Tsekoura (Thessaloniki, Greece)
| |
Survival of hypercapnic COPD patients is predicted by smoking habits, co-morbidity and hypoxaemia
T. A. C. Nizet, F. J. J. van den Elshout, Y. F. Heijdra, M. J. T. van de Ven, P. G. H. Mulder, H. T. M. Folgering (Arnhem, Nijmegen, Rotterdam, Groesbeek, The Netherlands)
| |
Six minute walk testing components as predictors of mortality in COPD
J. M. Marin, S. J. Carrizo, J. E. Alonso, A. Sanchez, J. De Pablo (Zaragoza, Spain)
| |
Effects of NAC on outcome variables in COPD patients
M. L. Decramer, M. Rutten-Von Mölken, R. P. N. Dekhuijzen, T. Troosters, I. Lankhorst, B. Investigators (Leuven, Belgium; Rotterdam, Nijmegen, The Netherlands; Bresson, Italy)
| |
Effect of long-term therapy with short-acting β2-agonist on left ventricle systolic function in patients with chronic obstructive pulmonary disease
T. O. Pertseva, T. S. Onyshchenko, L. I. Konopkina (Dnipropetrovsk, Ukraine)
| |
Does the duration of symptoms pre admission influence the clinical course of the exacerbation in COPD?
N. Duffy, F. Diamantea, P. Walker, P. M. A. Calverley, L. Davies (Liverpool, United Kingdom)
| |
Accuracy of emergency room diagnostic coding in patients admitted with acute exacerbations of COPD
T. K. Marras, K. M. Sanders, C. K. N. Chan, J. Yang, S. Aaron, M. S. Balter (Toronto, Ottawa, Canada)
| |
Relationship between quality of life and severity of COPD according to GOLD classification
C. Lisboa, O. Trujillo, A. Leiva, G. Borzone, O. Diaz (Santiago, Chile)
| |
Generic quality of life in COPD patients
M. T. J. Groenen, E. C. Creutzberg, R. Mostert, E. F. M. Wouters (Horn, Maastricht, The Netherlands)
| |
Depressive symptoms among COPD patients are associated with increased healthcare utilization
D. Coultas, B. Barnett, G. Singh, D. Edwards, P. Wludyka (Jacksonville, United States Of America)
| |
Patient perceptions of COPD exacerbations
C. Vogelmeier, C. G. Löfdahl, T. Larsson (Marburg, Germany; Lund, Sweden)
| |
Effect of salbutamol on arterial blood gas tensions in patients with stable hypercapnic chronic obstructive pulmonary disease
C. I. Whale, M. P. Sovani, K. Mortimer, T. W. Harrison, A. E. Tattersfield (Nottingham, United Kingdom)
| |
Estimating cost-effectiveness (CE) of seretide in COPD as cost per quality adjusted life year (QALY)
Y. Punekar, A. Gulsvik, J. A. Istad, M. Spencer (Greenford, United Kingdom; Bergen, Oslo, Norway)
| |
Health-related quality of life of patients with COPD
Y. Havlucu, P. Celik, G. Dinc, A. Sakar, A. Yorgancioglu (Manisa, Turkey)
| |